; and (B) an agreement described under section 505(j)(5)(B)(vii)(I) of the Federal Food, Drug, and Cosmetic Act (as added by subsection (a)(1)) executed after the date of enactment of this Act. (2) Notification of FDA The amendments made by paragraphs (2) and (3) of subsection (a) shall apply only with respect to an agreement described under section 505(j)(5)(B)(vii)(I) of the Federal Food, Drug, and Cosmetic Act (as added by subsection (a)(1)) executed after the date of enactment of this Act. 404. Increasing drug competition and preventing drug shortages Section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j)(7) ) is amended by adding at the end the following: (D) (i) The Commissioner shall— (I) not later than 9 months after the date of enactment of the Affordable Medications Act , publish a complete, up-to-date list on the internet website of the Food and Drug Administration of all drugs, including authorized generics, together with, with respect to the drug, as applicable— (aa) the drug trade name; (bb) the established name; (cc) each active pharmaceutical ingredient facility (as defined in section 744B(a)(4)(a)(ii)); (dd) each generic drug facility; (ee) each contract manufacturing organization facility (as defined in section 744A(5)); (ff) the date any authorized generic drug entered the market; (gg) the marketing status; and (hh) any other information the Secretary may require to mitigate or prevent drug shortages; (II) designate each drug on the list that is a sole-source generic drug; (III) designate each drug on the list that is an essential medicine, as identified by the World Health Organization, or another entity designated by the Secretary that meets evidence-based standards as required by the Secretary